Peptide education
Bronchogen
Bronchogen is a Khavinson-lineage tetrapeptide sold on a lung-repair story, and even its sequence is disputed: the patent family says Ala-Glu-Asp-Leu (AEDL), while at least two indexed papers say Ala-Asp-Glu-Leu (ADEL), the same four amino acids in a different order, indistinguishable by mass. Behind that confusion sits genuinely interesting preclinical work in bronchial cells and rodent lung-injury models. The human record is a Russian supplement label and a company brochure.
Bronchogen has the most interesting lab file of the respiratory bioregulators and almost no human evidence: no controlled trial, an unresolved AEDL-versus-ADEL sequence conflict, and a market split between 100 microgram Russian capsules and 20 mg research vials.
Overview
Quick answer
The name Bronchogen points to more than one product description. Patent and many vendor listings describe Ala-Glu-Asp-Leu, or AEDL. At least two indexed papers describe Ala-Asp-Glu-Leu, or ADEL. Those are positional isomers, not the same sequence. Russian pharmacy materials describe 100 microgram oral supplement capsules, while Western peptide vendors commonly list 20 mg lyophilized research vials. Sequence, route, dose, and product form all change what a claim can mean.
What is it?
A tetrapeptide respiratory bioregulator from the Khavinson research lineage. The patent family names AEDL; some papers use ADEL. The mismatch matters because every DNA-binding and cell-signaling claim depends on the exact residue order.
Why is it discussed?
The preclinical file is real: bronchial epithelial cell studies reporting marker changes, DNA-thermostability work, and rodent lung-injury models. Vendors and forums turn that into COPD, asthma, smoking-damage, and long-COVID claims, which is a much larger leap than the sources make.
What route and exposure details are documented?
The clearest schedule is the Russian supplement label: 100 microgram capsules, 1 to 2 capsules 1 to 2 times daily for a month, repeated after 4 to 6 months. Patent rodent examples used 0.2 micrograms/kg intraperitoneally; the 2014 bronchial-cell paper used 20 ng/mL in culture. Western vendors sell 20 mg vials with no defensible human schedule attached.
Does it have strong human evidence for lung disease?
No. The human material is a supplement label and a company brochure claiming 73% subjective improvement in chronic bronchitis with an asthmatic component, without visible methods, statistics, or peer review. That is the whole file.
How should readers judge it?
As a promising preclinical peptide with an identity problem and no human trial. Sequence first (AEDL or ADEL), then product form (capsule or vial), then the evidence, in that order.
Reported practice
Commonly reported protocol
Russian supplement label courses. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Patents, bronchial-cell experiments, DNA studies, and rodent lung-injury models support a preclinical respiratory-bioregulator case. Clinical benefit in people has not been shown.
The human material is a Russian supplement label and a company brochure with chronic-bronchitis claims. A modern peer-reviewed human trial with extractable methods and outcomes has not surfaced in the cited sources.
The patent family and several later papers or listings use AEDL, while the DNA thermostability paper and the 2014 Lung paper use ADEL. A purity number or expected mass alone may not resolve that sequence-order problem.
Vendor pages list research-use Bronchogen vials, commonly around 20 mg, with respiratory-repair marketing and partial analytical documents. Those pages show market and product-quality information, not efficacy.
Patent and brochure toxicology claims leave the key safety questions open: human adverse-event rates, interactions, reproductive risk, long-term exposure, and high-dose injected gray-market use.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Bronchogen treats COPD, asthma, chronic bronchitis, or long COVID. | Strong peer-reviewed human efficacy evidence for these conditions was not found. The material instead includes Russian supplement labeling, a company brochure chronic-bronchitis claim, rodent obstructive-lung models, and forum discussion. | Bronchial-cell and rodent models make respiratory interest plausible, but cell signaling and animal injury readouts fall short of disease-treatment evidence in people. | Reddit and vendor discussion includes asthma, lung healing, smoking damage, long COVID, and dosage questions. Those reports show what people are talking about, not whether Bronchogen works. | The lung-disease rationale is plausible but thin. The available sources are useful for understanding why people are interested and what product risks matter, not for calling Bronchogen a proven COPD, asthma, chronic-bronchitis, or long-COVID treatment. |
| Bronchogen supports bronchial epithelial repair. | The cited human material is supplement and brochure material rather than modern respiratory endpoint trials. The strongest repair evidence here is cell and animal work. | The 2014 bronchial-cell paper reported changes in proliferation, apoptosis-related, differentiation, mucus, and surfactant-associated markers in human embryonic bronchial epithelial cultures. Earlier work also reported Hoxa3 effects in bronchial cell cultures. | Vendor pages often translate this biology into pulmonary repair or respiratory tissue support language. | Plausible preclinical wording is fair. Human repair or treatment wording needs stronger patient data than the sources provide. |
| Bronchogen binds DNA and changes gene expression. | This result describes a mechanism experiment, not a patient result. | The DNA thermostability paper reported a 3.1 C increase in DNA melting temperature in a narrow molar-ratio range. A later docking paper proposed a ctcc DNA motif interaction for AEDL. That work supports a mechanism hypothesis, not clinical efficacy. | Vendor and bioregulator marketing sometimes turns DNA-language into broad regeneration claims. | Mechanism findings should stay tied to the AEDL/ADEL sequence conflict. |
| Bronchogen is safe because patents and brochures say it was non-toxic. | Patent toxicology examples and brochure claims do not replace modern human safety data. | The main mechanistic safety question is long-term exposure. Bronchial-cell proliferation, apoptosis-marker, differentiation, and gene-expression changes may be relevant to repair hypotheses, but they also make chronic-use claims harder to treat casually. | A vendor SDS describes limited published toxicological characterization and research-use handling precautions. | Clinical safety is not well characterized, including human safety, interactions, reproductive risk, long-term exposure, and injected-vial safety. |
| A 20 mg research vial is equivalent to the Russian capsule product. | There is no evidence that the Russian oral capsule product and Western lyophilized research vials are equivalent. | Route, dose, formulation, sequence identity, purity, sterility, and bioavailability all affect comparability. | Western vendors commonly list 20 mg research vials, while Russian pharmacy materials describe 100 microgram capsules. | No. Oral capsules and research vials create different dose, route, and quality questions around Bronchogen. |
| A COA confirms pharmaceutical-grade Bronchogen. | A COA is not a human efficacy or safety study. | Because AEDL and ADEL have the same amino-acid composition and nominal mass, mass plus HPLC purity may not be enough to settle sequence order. | The NovoPro COA reported AEDL acetate salt, MS mass 446.35, and 99.731% HPLC purity, but listed endotoxin, moisture, TFA solubility, and acetic acid content as N/A. Vendor SDS material also limits the product to in vitro research use. | A COA can be a limited clue. It cannot show sterile injectable quality, clinical equivalence, or complete identity control. |
Bottom line
Main takeaway
Bronchogen is a respiratory research peptide with good lab data and no proven human benefit. It is not a dependable COPD, asthma, or lung-repair therapy.
Separate four things the market merges: the patent and cell-culture research, the Russian 100 microgram capsule, the company brochure, and the 20 mg gray-market vial. Same name, different realities, and the sequence itself is in dispute.
Start with the AEDL-versus-ADEL conflict, because it conditions everything downstream, then read the DNA-thermostability paper, the 2014 Lung bronchial-cell paper, the patent rodent examples, and the label and brochure material. The gap you will not find filled is a modern clinical trial.
Identity
What it is
The patent family presents Bronchogen as Ala-Glu-Asp-Leu, a tetrapeptide for restoring respiratory-organ function. Some indexed papers call the same name Ala-Asp-Glu-Leu. Same composition, different order, and a standard mass spec cannot tell them apart.
The preclinical file earns the interest. A DNA-thermostability study reported a 3.1 C rise in DNA melting temperature; bronchial epithelial cultures exposed to 20 ng/mL showed shifts across proliferation, differentiation, mucus, and surfactant markers; patent rodent examples covered bacterial injury, bleomycin fibrosis, and hyperoxia. This is a real research program.
The human file is a label and a brochure: a Russian 100 microgram oral supplement with a month-long course schedule, and a company brochure claiming 73% versus 62% subjective improvement in chronic bronchitis with an asthmatic component. No modern trial, no peer review, no adverse-event table.
The market completes the picture: 20 mg research vials, COAs that leave endotoxin and moisture fields blank, and a vendor SDS restricting the material to in vitro research. None of that connects cleanly to the Russian capsule, let alone to a patient.
How people talk about it online
Forum and vendor talk clusters around asthma, COPD, smoking damage, mucus, lung healing, and long COVID, plus dosage questions that have no studied human schedule to anchor to.
Vendor pages pair respiratory-repair language with research-use-only disclaimers, commonly around 20 mg vials. The paperwork tells its own story: COAs that leave sterility, endotoxin, and moisture questions open, and one SDS that limits the material to in vitro use.
The comparison shoppers should notice is scale: 20 mg vials versus 100 microgram capsules, a 200-fold difference in nominal content between two products sharing a name and a claim list.
Use context
Routes, doses, and cycle patterns
Bronchogen has no FDA label in these sources. The concrete numbers come from separate places: patent animal examples, a bronchial-cell study, Russian capsule labeling, and vendor vial listings. The practical mistake would be blending them into one regimen. An animal model, cell-culture exposure, supplement label, brochure claim, vendor page, COA, SDS, and forum report answer different questions.
Human studies and product labels
Patent rodent bacterial lung-injury example
- Purpose
- Acute bacterial lung injury model
- Context
- Patent preclinical example
- Route
- Intraperitoneal in rodents
- Amount
- 0.2 micrograms/kg
- Frequency
- Once daily
- Duration
- 7 days, starting 2 days after infection
This is an animal patent example. It supports preclinical interest in lung-injury models and gives one concrete route/amount pattern from the cited patent.
Patent bleomycin lung-fibrosis example
- Purpose
- Rat bleomycin lung-fibrosis model
- Context
- Patent preclinical example
- Route
- Intraperitoneal in rodents
- Amount
- 0.2 micrograms/kg
- Frequency
- Reported as a 7-day treatment period after bleomycin exposure
- Duration
- 7 days, beginning on day 5 after each bleomycin installation
This model helps frame preclinical lung-injury research and gives another concrete animal-study exposure pattern.
Patent hyperoxic lung-injury example
- Purpose
- Sublethal hyperoxic lung injury in rats
- Context
- Patent preclinical example
- Route
- Intraperitoneal in rodents
- Amount
- 0.2 micrograms/kg
- Frequency
- Every other day
- Duration
- 10 injections, beginning on day 3 after return to normal atmosphere
This is a patent example in a controlled animal injury model. Human oxygen-injury or recovery claims would need patient evidence.
Bronchial-cell culture exposure
- Purpose
- Human embryonic bronchial epithelial cell signaling
- Context
- In vitro Lung 2014 paper
- Route
- Cell culture exposure
- Amount
- 20 ng/mL
- Frequency
- Experimental culture exposure
- Duration
- Culture-specific experimental period
The paper reported changes in Ki67, Mcl-1, p53, CD79, NOS-3, NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2, MUC4, MUC5AC, and SFTPA1. This is mechanistic and cellular evidence, not a clinical dose.
Russian supplement label course
- Purpose
- Commercial supplement context for respiratory support claims
- Context
- Russian pharmacy and reference label material
- Route
- Oral capsule
- Amount
- 100 micrograms peptide complex per capsule.
- Frequency
- 1 to 2 times daily
- Duration
- 1 month; repeat after 4 to 6 months in the label material
This is the clearest product schedule here. It comes from supplement label material, not from a peer-reviewed clinical trial.
Real-world discussion
Russian supplement label courses
- Purpose
- Respiratory discussion
- Context
- Russian supplement labeling and bioregulator vendors
- Route
- Oral capsules
- Amount
- 100 microgram capsules, 1 to 2 capsules 1 to 2 times daily in label language
- Frequency
- Once or twice daily during a course
- Duration
- A month-long course, repeated after 4 to 6 months in label language
Western vendors sell 20 mg vials with no defensible human schedule attached. Shared here as context, not instruction.
What varies
- Sequence: AEDL and ADEL both appear in circulation, and that affects every mechanism and product-identity claim.
- Product form: 100 microgram oral capsules and 20 mg research vials are not interchangeable product contexts.
- A rodent lung-injury model, a Russian capsule label, a vendor COA, and a Reddit post answer different questions.
- Route: oral supplement labeling, intraperitoneal rodent dosing, cell-culture exposure, and research-vial commerce should be kept separate.
- Amount: 0.2 micrograms/kg in rodents, 20 ng/mL in cell culture, 100 micrograms per capsule, and 20 mg vials are not interchangeable human-use amounts.
- Product quality: identity, sequence order, sterility, endotoxin, moisture, counterion, residual solvents, storage, and chain-of-custody matter more than a single purity percentage.
Human data
Human evidence
Nearly empty. The human material is a Russian supplement label, which is a product schedule rather than a trial, and a company brochure reporting 73% subjective improvement versus 62% control in chronic bronchitis with an asthmatic component, with no visible methods, statistics, or adverse-event collection. Everything stronger is preclinical: DNA interaction, bronchial-cell signaling, and rodent lung-injury models. There is no controlled human lung trial in the cited record.
Evidence maturity
Bronchogen's support stops at preclinical lung biology and supplement-label material; no controlled human lung trial exists.
DNA thermostability experiments and bronchial epithelial cell studies report marker changes tied to proliferation, differentiation, and mucus biology.
Patent examples describe bacterial injury, bleomycin fibrosis, and hyperoxia models treated with AEDL.
A Russian supplement label and a company brochure claim chronic-bronchitis benefit, but no peer-reviewed modern trial has surfaced.
100 microgram Russian capsules and 20 mg gray-market vials coexist under an unresolved AEDL-versus-ADEL sequence conflict.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Russian Bronchogen supplement label | Consumers using a Russian biologically active supplement | Label and pharmacy reference material | Oral supplement capsule, not an approved medicine | Provides the clearest listed product schedule: 100 micrograms per capsule, 1 to 2 capsules 1 to 2 times daily for 1 month, with repeat courses after 4 to 6 months. | A supplement label is not a clinical trial. It supplies no efficacy, adverse-event rates, comparative benefit, or equivalence to research vials. | Weak product-label support |
| Company brochure chronic-bronchitis claim | People described in manufacturer-style chronic bronchitis material | Company brochure summary | Manufacturer or distributor claim context | The brochure claims adjunctive benefit in chronic bronchitis with an asthmatic component and reports 73% subjective improvement versus 62% in control, with no side effects observed. | The brochure lacks enough detail on sample size, randomization, comparator handling, endpoints, publication status, statistics, or adverse-event collection. | Very weak human claim |
| Bronchial-cell and DNA mechanism papers | DNA samples and human bronchial epithelial cell cultures | Biophysics and in vitro experiments | Laboratory research peptide | Those papers report DNA thermostability effects, Hoxa3 changes, and bronchial epithelial marker changes tied to proliferation, differentiation, apoptosis-related markers, mucus genes, and surfactant biology. | These studies measured no patient symptoms, exacerbations, lung function, quality of life, infections, or long-term safety. | Preclinical |
| Rodent lung-injury and obstructive-lung models | Rodent lung-injury or COPD-like models | Patent animal examples and PubMed abstract-level animal model work | Preclinical research peptide | The animal work supports interest in bacterial injury, fibrosis, hyperoxia, obstructive-lung pathology, epithelial remodeling, and inflammatory activity. | Rodent injury models do not answer whether Bronchogen helps human COPD, asthma, chronic bronchitis, smoking-damage, or long-COVID symptoms. | Preclinical |
Cautions
Safety and unknowns
- Modern human safety data were not found for adverse-event rates, dose-response, interaction risk, long-term exposure risk, reproductive safety, cancer-relevant signaling risk, or high-dose injected-vial safety.
- Patent and brochure toxicology claims are early or manufacturer-associated safety assertions, not contemporary human pharmacovigilance.
- The vendor SDS describes limited published toxicological characterization, no assigned CAS number, no harmonized CLP classification, and no chemical safety assessment by the supplier.
- The AEDL-versus-ADEL sequence conflict increases safety uncertainty because the public market may not be standardized to one exact peptide sequence.
- Because Bronchogen claims involve bronchial-cell proliferation and gene-expression changes, long-term safety, product identity, and handling conditions still matter.
Product quality
A vial label is only a starting point
Product identity needs checking because AEDL and ADEL both appear.
A 100 microgram oral supplement capsule and a 20 mg lyophilized research vial create completely different exposure and quality problems.
A public COA with mass and HPLC purity can still miss the questions that matter for this peptide: AEDL versus ADEL sequence order, sterility, endotoxin control, moisture, counterion content, residual solvents, storage stability, and representative lot release.
Research-use disclaimers and non-authorization language on vendor documents matter because they separate market availability from medical product status.
Exact sequence
AEDL and ADEL have the same amino-acid composition but different order. Orthogonal sequence confirmation is needed before borrowing claims from one context into another product.
Sterility and endotoxin
HPLC purity cannot show sterile injectable quality or endotoxin control.
Dose and formulation
The label pattern is built around 100 microgram capsules, while vendors commonly sell 20 mg vials.
Documentation completeness
COAs and SDS documents may omit values that matter for clinical-grade release.
Regulatory status
Russian supplement status, patent claims, and Western research-use sales fall short of medicine authorization.
Mechanism
How it is proposed to work
The proposed Bronchogen mechanism is a short-peptide bioregulation model: a tiny peptide may enter cells, interact with DNA or promoter regions, and shift gene programs involved in bronchial epithelial differentiation, proliferation, apoptosis-related signaling, mucus biology, and surfactant biology. That is plausible laboratory biology; it still has not shown symptom or lung-function improvement in people.
The DNA thermostability paper reported a 3.1 C increase in DNA melting temperature at a narrow peptide-to-DNA molar range, with the authors interpreting the interaction as involving both DNA strands and mainly nitrogenous bases.
The 2012 bronchial-cell paper reported increased Hoxa3 expression area in young, mature, and aged bronchial epithelial cultures, while CXCL12 showed no significant change in those cultures.
The 2014 Lung paper reported changes in Ki67, Mcl-1, p53, CD79, NOS-3, NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2, MUC4, MUC5AC, and SFTPA1 after 20 ng/mL exposure in human embryonic bronchial epithelial cultures.
The 2016 docking paper proposed a ctcc DNA motif interaction for AEDL. That claim becomes less secure if the material being discussed is ADEL instead of AEDL.
Bronchogen (Ala-Glu-Asp-Leu) is a Khavinson-lineage tetrapeptide positioned for respiratory claims. Its support is the lineage's preclinical literature; no controlled human data exist.
FAQ
Common questions
What is bronchogen?
Bronchogen is a Khavinson-lineage bioregulator peptide positioned for respiratory claims. Its evidence is the Russian bioregulator literature plus animal and cell work.
What do bioregulator courses look like?
The clearest documented schedule is the Russian supplement label: 100 microgram capsules, 1 to 2 capsules 1 to 2 times daily for a month, repeated after 4 to 6 months. Western 20 mg vials have no defensible human schedule attached.
Is there human evidence?
Nothing meeting controlled-trial standards. The claims rest on the lineage's own publications.
Details
Technical details
Sources
References
- 1.
Khavinson respiratory patent. EP1758922A1 / related Khavinson patent family, “Peptide substance restoring function of respiratory organs”
Patent
- 2.
Tissue-specific differentiation paper. Khavinson et al., 2012, “Peptides Tissue-Specifically Stimulate Cell Differentiation during Their Aging”
Primary paper
- 3.
Lung bronchial-cell paper. Basharina et al., 2014, Lung 192:781-791
Primary paper
- 4.
Obstructive-lung animal abstract. Titova et al., 2017, PubMed abstract on obstructive-lung pathology model
Primary abstract
- 5.
Peptide-regulation reviews. 2020 review plus 2021 systematic review on peptide regulation
Review literature
- 6.
Russian Bronchogen listings. RLS, eApteka, Apteka.ru Bronchogen listings
Label / pharmacy reference
- 7.
Peptidebio Bronchogen brochure. Peptidebio Bronchogen brochure PDF
Company brochure
- 8.
Ion Peptide vendor page. Ion Peptide Bronchogen 20 mg
Gray-market vendor
- 9.
Nationwide Peptides vendor page. Nationwide Peptides Bronchogen page
Gray-market vendor
- 10.
NovoPro Bronchogen COA. NovoPro Bronchogen COA PDF
Public COA
- 11.
UK Peptides Bronchogen SDS. UK Peptides Bronchogen SDS
Vendor SDS
- 12.
Uther Peptide testing page. Uther Peptide plus linked Janoshik report page
Vendor plus third-party test portal
- 13.
Additional vendor examples. Additional vendor price and stock examples
Gray-market vendor signal
- 14.
Reddit respiratory discussions. Reddit discussion threads surfaced by search
Social anecdote